Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neurodevelopmental outcome after FNAIT with or without maternal IVIg exposure
NL-OMON49430Active, not recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Dec 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of immune globulin in fetomaternal alloimmune thrombocytopenia (FMAIT) (2 arms), sponsored by Leiden University Medical Center. Primary endpoint: Cognitive development. Started Dec 2019; status: active, not recruiting.
02
Drugs
immune globulin
03
Conditions
fetomaternal alloimmune thrombocytopenia (FMAIT)
Beyond the preview
Go deeper on NL-OMON49430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49430.